Association of combination tumor texture and vessel tortuosity with progression free survival across PD-L1 subgroups in durvalumab treated non-small cell lung cancer (NSCLC): Blinded validation results from CP1108.

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Clinical Oncology

Topics

Medicine

Cancer Oncology

Pathology

Internal Medicine

Radiology, Nuclear Medicine And Imaging

Show all topics

DOI

10.1200/jco.2024.42.16_suppl.8600